Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(34 sites)
Japan
National Cancer Center Hospital East, Chiba Ehime Prefectural Central Hospital, Ehime Kyushu University Hospital, Fukuoka National Hospital Organization Kyushu Cancer Center, Fukuoka National Hospital Organization Kyushu Medical Center, Fukuoka Gifu University Hospital, Gifu Hirosaki University Hospital, Hirosaki Hiroshima University Hospital, Hiroshima St. Marianna University Hospital, Kawasaki University of Occupational and Environmental Health Hospital, Kitakyushu Kochi Medical School Hospital, Kochi Kumamoto University Hospital, Kumamoto Kyoto Prefectural University of Medicine, Kyoto Nagoya University Hospital, Nagoya Ohara Memorial Kurashiki Central Medical Organization Kurashiki Central Hospital, Okayama Okayama University Hospital, Okayama Kansai Medical University Hospital, Osaka Kindai University Hospital, Osaka National Hospital Organization Osaka Medical Center, Osaka Osaka International Cancer Institute, Osaka Osaka Metropolitan University Hospital, Osaka Osaka Prefectural Hospital Organization Osaka Acute and General Medical Center, Osaka Osaka University Hospital, Osaka Kitasato University Hospital, Sagamihara Sapporo Medical University Hospital, Sapporo Keio University Hospital, Tokyo National Cancer Center Hospital, Tokyo Nippon Medical School Hospital, Tokyo Tokyo Medical University Hospital, Tokyo Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Komagome Hospital, Tokyo Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama Yokohama City University Hospital, Yokohama Yokohama City University Medical Center, Yokohama Federation of National Public Service Personnel Mutual Aid Associations Yokosuka Mutual Aid Hospital, Yokosuka